retatrutide phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Each adjustment occurs every 4 weeks based on individual tolerance

Read the full article in Journal of Substance Abuse Treatment: Learn more about the implementation research in addiction: #ImplementationScience #AddictionResearch #EvidenceBased #NIH #NIDA #PublicHealth #ResearchToPractice To view or add a comment, sign in Seventeen Years of Progress in NIDAs Investment in Implementation Research: How Far Weve Come

GLP-1 receptor agonists suppress appetite and slow gastric emptying, which commonly leads to rapid, substantial weight loss: often 1520% of total body weight within a year

For this analysis, we surveyed 10,133 U.S